Navigation Links
Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
Date:6/9/2009

Leiden, The Netherlands, June 09, 2009 / b3c newswire / - Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna’s viral gene delivery platform SVac. Under this agreement, TNO will develop novel methods for the manufacture, formulation and testing of viral gene delivery systems such as the SVac platform of Amarna. The collaboration is partly supported by a co-financing initiative aimed at developing innovative technologies.

“We are very pleased to work with TNO”, said Ben van Leent, CEO of Amarna Therapeutics. “We have developed a revolutionary novel viral gene delivery vector platform technology SVac for producing human therapeutics that have the potential to save lives and improve the quality of life for millions of people worldwide that are suffering from life-threatening or severe chronic diseases. The technology is now available to address the major diseases of our time including genetic disorders, autoimmune diseases, allergies and cancer. Amarna Therapeutics acts at the forefront of the therapeutic vaccination and gene therapy markets. Both markets are rapidly growing to reach an estimated 40 billion Euro’s in 2015. I’m convinced that the therapeutics in our pipeline all have blockbuster potential. The partnership with TNO enables us to initiate the first time in man clinical trials with one of our lead therapeutics in 2010.”

“The partnership between TNO and Amarna allows us to expand our pre-clinical development services into the extremely important therapeutic area of viral vector and gene delivery technologies and is yet another important step in our establishment of a fully integrated and highly innovative package of biopharmaceutical development capabilities” says Menzo Havenga, Managing Director of Biosciences at TNO.


About Amarna Therapeutics
Amarna Therapeutics B.V. is a Biotechnology company that develops therapeutic vaccinations to treat immunity-associated diseases including autoimmune diseases, allergies and cancer and gene therapies to treat genetic disorders. The base of Amarna’s therapeutics is the SVac viral gene delivery vector platform, which provides sensational characters unheard of in the Pharma arena, creating opportunities to serve markets with enormous potential due to clinical unmet needs.

About SVac
Our SVac viral gene delivery vector platform has a number of unique properties compared to other viral gene delivery vectors such as lentiviral, poxviral, alphaviral, adenoviral and adeno-associated virus (AAV) vector systems. SVac is non-immunogenic in humans, highly stable, safe to use and can be cost effectively produced in large amounts in a proprietary producer cell line denoted SuperVero. Moreover, the vector has extensively been tested for safety in model animals. The SuperVero cell line has been qualified and tested using Quality Control (QC) assays and its use for manufacturing clinical trial material has been validated. The whole vector production process is similar to the current manufacturing processes of the polio, rabies and influenza virus vaccines in which a master seed virus is seeded to producer cells in large fermentors. Because of its immunological inertia in man SVac is the only vector system known that is suitable for for treating genetic disorders and immunity associated diseases.

About TNO
TNO is a prominent, independent knowledge company whose expertise and research contribute significantly to the competitiveness of businesses and organizations, to the economy and to the quality of life as a whole. Its versatility and capacity to integrate a broad diversity of sciences and technologies makes TNO unique. TNO employs about 4300 professionals in five core areas: TNO Quality of Life, TNO Defense, Security and Safety, TNO Science and Industry, TNO Built Environment and Geosciences, TNO Information and Communication Technology.
Within biopharmaceutical development, TNO’s mission is to optimize and accelerate the transition of human therapeutics from discovery to the clinic. TNO strives towards this goal by establishing innovative product development and manufacturing technologies and applying them in a fully integrated package of pre-clinical development services.


For further information please contact:


For Amarna Therapeutics:

Ben van Leent
T: +31 71 3322192
M: +31 6 47566999
F: +31 71 3322195
E: ben.vanleent@amarnatherapeutics.com
W: www.amarnatherapeutics.com

For TNO:
Heather Wagner
T: +31 (30) 6944615
M: +31 (6) 23296045
E: heather.wagner@tno.nl
W: www.tno.nl/pharma


'/>"/>
b3c newswire

Related biology news :

1. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
2. NIH announces new program to develop therapeutics for rare and neglected diseases
3. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
4. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
5. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
6. A novel target for therapeutics against Staph infection
7. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
8. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
9. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
10. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
11. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... READING, England , May 26, ... ), a leading global provider of clinical, commercial ... healthcare organisations and TranScrip ( http://www.transcrip-partners.com ), a ... the product lifecycle, today announced the extension of ...      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ) ...
(Date:5/26/2016)... , May 26, 2016 Despite ... see value in this space. Today,s pre-market research on ActiveWallSt.com ... Radius Health Inc. (NASDAQ: RDUS ), Cerus Corp. ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... announced several positive developments that position the Company for the future. Kinder ... transaction, Craig F. Kinghorn has been appointed Chairman of the Board, Curtis D. ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a ... consistently been rated one of its top attractions. Fortune 500 companies, such as ... in a unique and intimate team-building experience. , Each event kicks off with an ...
Breaking Biology Technology: